Lead sponsor
Bristol-Myers Squibb
20 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
20
Trials led
7
Ongoing
4,123
Total enrollment
941
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
11
Phase 2
3
Phase 3
6
Trials by status
Recruiting
6
Active, not recruiting
1
Completed
12
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Study partner/caregiver requiredPh 3Recruiting650
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Alzheimer's diseasePh 3Recruiting426
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Alzheimer's diseasePh 3Recruiting352
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)Alzheimer's diseasePh 3Recruiting325
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Diseaseprodromal ADPh 2Terminated263
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed209
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163Age ≥18Ph 1Completed116
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsHealthy volunteersPh 1Completed62
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's DiseaseAge 50-90Ph 1Completed40
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseAge 18-45Ph 1Completed36
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163Age ≥18Ph 1Completed32